Results 191 to 200 of about 306,421 (309)

Nanomedicine Meets Immunotherapy: Advancing Adoptive Cell Therapy with Nanoparticles in the Treatment of Cancer with Sustainability Perspectives

Advanced Science, EarlyView.
This review surveys nanoparticle‐based strategies to enhance adoptive cell therapy, particularly CAR‐T cell approaches, in solid tumor treatment. It describes how nanoparticles can improve tumor immunogenicity and T‐cell infiltration while reducing toxicity, and how they enable in vivo CAR‐T cell generation.
Erica Frostegård, Tatiana Bobrova, Amalie Leinebø, Thibault Leray, Shayamita Ghosh, Lorena García‐Hevia, Chiara Puccinelli, Lorenzo Riccio, Jacopo Sorani, Davide Bonifazi, Julien Caumartin, Emmanuel Donnadieu, Florence Gazeau, Roland Hischier, Else Marit Inderberg, Mónica L. Fanarraga, Maria Loustau, Bernd Nowack, Sébastien Wälchli, Cécilia Ménard‐Moyon   +19 more
wiley   +1 more source

Why Is MS a More Frequent Complication of EBV Infection in Females? [PDF]

Immunol Rev
Dunn SE, Alvarez-Sanchez N, Steinman L.
europepmc   +1 more source

A Nanobody‐LNP Platform for Targeting and Relicensing Dendritic Cells for Potent Cancer Immunotherapy

Advanced Science, EarlyView.
Plastin‐2 (PLS2) is identified as a dual‐function receptor on DCs that mediates both nanoparticle uptake and immunomodulation. A nanobody‐LNP platform is engineered to integrate antigen delivery with relicensing DCs. The therapeutic strategy elicits potent anti‐tumor T cell responses and leads to significant inhibition of established tumors in vivo ...
Shugang Qin, Zhiying Huang, Hai Huang, Yupei Zhang, Yuting Chen, Xi He, Zhenyi Niu, Zhongzheng Xiang, Chaoyu Zou, Xiangrong Song   +9 more
wiley   +1 more source

Cytokines Associated with Activation of CD4⁺CD25⁺Foxp3⁺ T Regulatory Cells. [PDF]

Int J Mol Sci
Al-Atiyah R, Verma ND, Tran GT, Hodgkinson SJ, Hall BM.   +4 more
europepmc   +1 more source

ROS Self‐Supply Nanoplatform Based on Fenton Catalyst for Chemodynamic and Immunotherapy: Reprogramming Cold Tumor Into Hot Tumor in Cancer Treatment

Advanced Science, EarlyView.
A multifunctional HA‐conjugated nanoplatform (HA‐PGMC) integrates CuO2, glucose oxidase, and mil‐100 to enable cascade catalytic ROS generation in tumor microenvironments. This self‐supplying ROS strategy induces immunogenic cell death, reprograms “cold” tumors into “hot” ones, and synergizes with PD‐L1 blockade, achieving potent chemodynamic ...
Man Lung Lee, Jack Chun Hin Chen, Wai Wing Cheng, Kwan Yee Lau, Hiu Yee Kwan, Ngar‐Yun Ellen Poon, Hung‐Wing Li   +6 more
wiley   +1 more source

Immune modulatory vaccines targeting tumor microenvironment antigens: recent advances in oncology and beyond. [PDF]

Signal Transduct Target Ther
Andersen MH.
europepmc   +1 more source

Early Detection and Inhibition of Post‐Surgical Cancer Recurrence by Synthetic Extracellular Vesicles

Advanced Science, EarlyView.
An implantable hydrogel is designed to hold gene transfection agents engineered to turn early recurrent tumor cells into generators of synthetic EVs. These synthetic EVs can express engineered miR‐26a (E‐miR‐26a) for highly sensitive detection and PD‐1 (a PD‐L1‐blocking agent) for therapeutic intervention, thereby enabling early detection and ...
Junli Zhang, Wenjia Chang, Ruolin Hu, Peiyan Su, Qin Zhou, Yanan Li, Zhenzhong Zhang, Kaixiang Zhang   +7 more
wiley   +1 more source

Revisiting the past in light of current knowledge on γδ T cells in leishmaniasis. [PDF]

Front Immunol
Dos-Santos JS, de Matos Guedes HL.
europepmc   +1 more source

Albumin‐Bound STING Agonist Reprograms HSPCs to Antitumor Neutrophils Enhancing CD8+ T Cell Immunity

Advanced Science, EarlyView.
This study demonstrates that an albumin‐bound STING agonist (Nano ZSA‐51D) reprograms HSPCs to produce antitumor neutrophils with enhanced MHC I–mediated CD8+ T cell activation, thereby sensitizing tumors to α‐PD1 therapy. These findings highlight a strategy to target early hematopoiesis for shaping neutrophil fate and potentiating cancer immunotherapy.
Jinsong Tao, Hong‐Yi Zhao, Chengyi Li, Hanning Wen, Fang Ke, Qiuxia Li, Miao He, Bo Wen, Zhongwei Liu, Kai Sun, Wei Gao, Duxin Sun   +11 more
wiley   +1 more source

Nano‐Enabled Systemic Delivery of STING Agonist by Engineered Silicasome for Potent Antitumor Immunotherapy

Advanced Science, EarlyView.
Engineered mesoporous silica nanoparticles (Silicasomes) enable systemic delivery of the STING agonist ADU‐S100, overcoming the instability and toxicity that limit cyclic dinucleotides to local administration. By enhancing tumor accumulation, activating systemic antitumor immunity, and remodeling the tumor immune microenvironment, these nanoparticles ...
Wenjing Zhou, Yuting Li, Xudong Sun, Honghong Yang, Xiayu Shi, Lijia Yao, Jinhong Jiang, Erli Wang, Haoyang Wang, Yi Wei, Xiangsheng Liu   +10 more
wiley   +1 more source